KR102919982B1 - 거대고리 화합물 및 그의 용도 - Google Patents

거대고리 화합물 및 그의 용도

Info

Publication number
KR102919982B1
KR102919982B1 KR1020217020790A KR20217020790A KR102919982B1 KR 102919982 B1 KR102919982 B1 KR 102919982B1 KR 1020217020790 A KR1020217020790 A KR 1020217020790A KR 20217020790 A KR20217020790 A KR 20217020790A KR 102919982 B1 KR102919982 B1 KR 102919982B1
Authority
KR
South Korea
Prior art keywords
group
methyl
diseases
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217020790A
Other languages
English (en)
Korean (ko)
Other versions
KR20210099622A (ko
Inventor
시게미츠 마츠모토
료마 하라
나오요시 노구치
히데토 후쿠시
아유무 니이다
사토시 사사키
미노루 이코마
도시타케 고바야시
츠요시 마에카와
Original Assignee
가부시키가이샤 스코히아 파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70975488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102919982(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 가부시키가이샤 스코히아 파마 filed Critical 가부시키가이샤 스코히아 파마
Publication of KR20210099622A publication Critical patent/KR20210099622A/ko
Application granted granted Critical
Publication of KR102919982B1 publication Critical patent/KR102919982B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217020790A 2018-12-05 2019-12-04 거대고리 화합물 및 그의 용도 Active KR102919982B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2018-228234 2018-12-05
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Publications (2)

Publication Number Publication Date
KR20210099622A KR20210099622A (ko) 2021-08-12
KR102919982B1 true KR102919982B1 (ko) 2026-02-02

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020790A Active KR102919982B1 (ko) 2018-12-05 2019-12-04 거대고리 화합물 및 그의 용도

Country Status (18)

Country Link
US (1) US11518763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890738A4 (cg-RX-API-DMAC7.html)
JP (2) JP7895177B2 (cg-RX-API-DMAC7.html)
KR (1) KR102919982B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164468A (cg-RX-API-DMAC7.html)
AR (1) AR117251A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391942B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010704A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121952C (cg-RX-API-DMAC7.html)
CL (1) CL2021001451A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007304A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006527A (cg-RX-API-DMAC7.html)
NZ (1) NZ776102A (cg-RX-API-DMAC7.html)
PH (1) PH12021551262A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105125XA (cg-RX-API-DMAC7.html)
TW (1) TWI820266B (cg-RX-API-DMAC7.html)
UA (1) UA127872C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
BR112023004567A2 (pt) * 2020-09-14 2023-04-04 Sanofi Sa Derivados de tetrahidroisoquinolina para o tratamento de doenças do sangue e doenças inflamatórias
AU2024251986A1 (en) * 2023-04-03 2025-10-16 Acelink Therapeutics, Inc. Novel compounds and uses thereof
CN119707895B (zh) * 2023-12-18 2026-03-31 江苏苏中药业研究院有限公司 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法
WO2026026967A1 (zh) * 2024-08-02 2026-02-05 劲方医药科技(上海)股份有限公司 丙烯酰基类化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
EP3573963B1 (en) 2017-01-30 2021-09-01 Biogen MA Inc. Nrf2 activator
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181345A1 (ja) * 2017-03-28 2018-10-04 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
MX2021006527A (es) 2021-07-21
TWI820266B (zh) 2023-11-01
UA127872C2 (uk) 2024-01-31
KR20210099622A (ko) 2021-08-12
EP3890738A1 (en) 2021-10-13
WO2020116660A1 (en) 2020-06-11
SG11202105125XA (en) 2021-06-29
JP7895177B2 (ja) 2026-07-27
CA3121952A1 (en) 2020-06-11
CO2021007304A2 (es) 2021-06-21
AR117251A1 (es) 2021-07-21
US11518763B2 (en) 2022-12-06
JP2024123202A (ja) 2024-09-10
EP3890738A4 (en) 2022-08-17
CN113164468A (zh) 2021-07-23
TW202039494A (zh) 2020-11-01
BR112021010704A2 (pt) 2021-08-24
CL2021001451A1 (es) 2021-12-24
PH12021551262A1 (en) 2021-10-25
US20220119391A1 (en) 2022-04-21
AU2019391942B2 (en) 2024-03-21
AU2019391942A1 (en) 2021-06-03
CA3121952C (en) 2025-05-13
JP2022510736A (ja) 2022-01-27
NZ776102A (en) 2024-12-20

Similar Documents

Publication Publication Date Title
JP7253640B2 (ja) 複素環化合物およびその用途
US11518763B2 (en) Macrocyclic compound and use thereof
JP6832342B2 (ja) 複素環化合物
WO2018181345A1 (ja) 複素環化合物
KR20160113299A (ko) 헤테로시클릭 화합물
CN110678458A (zh) 用于治疗代谢紊乱的经取代的环基-乙酸衍生物
JP7862600B2 (ja) 複素環化合物
TW202042805A (zh) 雜環化合物
JPWO2020153414A1 (ja) 複素環化合物及びその用途
CN114728900A (zh) 杂环类的nmda拮抗剂
US12590086B2 (en) 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
JP2025539434A (ja) 複素環化合物及びその用途
RU2798235C9 (ru) Макроциклическое соединение и его применение
RU2798235C2 (ru) Макроциклическое соединение и его применение
JP7177042B2 (ja) 複素環化合物
JP7177043B2 (ja) 複素環化合物
JP2019196308A (ja) 複素環アミド化合物
JP7628955B2 (ja) 複素環化合物
WO2020067457A1 (ja) 縮合環化合物
JPWO2020067456A1 (ja) 複素環化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)